CEACAM5 and neoplasm: Results of early-phase clinical trials of DCs pulsed with exogenous tumor-associated peptides such as carcinoembryonic antigen (CEA) or with autologous tumor lysates demonstrated safety and immune-specific responses with no survival benefit [96].